Trial Profile
Phase II multicenter study of P210-B3A2 derived peptide vaccine in chronic myeloid leukemia patients in complete cytogenetic response with persistent residual disease during imatinib treatment
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Chronic myeloid leukaemia vaccine (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- 10 May 2007 New trial record.